Inventiva (CHIX:IVAP) EPS without NRI: €-1.30 (TTM As of Dec. 2025)


CHIX:IVAP Inventiva SA CHIX:IVAP
53 GF Score
Price €3.06
GF Value €0.24
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Inventiva EPS without NRI?

Inventiva CHIX:IVAP 53 EPS without NRI is €-1.30 as of Dec. 2025. GuruFocus rates CHIX:IVAP with a GF Score™ of 53/100 and a GF Value™ of €0.24 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,176 Biotechnology companies, Inventiva ranks worse than 63.01% on this metric.

Inventiva's earnings per share without non-recurring items for the six months ended in Dec. 2025 was €-0.70. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.30.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 6.30% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -11.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Inventiva's EPS without NRI or its related term are showing as below:

CHIX:IVAp' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -45.9   Med: -10.45   Max: 17.1
Current: 6.3

During the past 13 years, Inventiva's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 17.10% per year. The lowest was -45.90% per year. And the median was -10.45% per year.

CHIX:IVAp's 3-Year EPS without NRI Growth Rate is ranked worse than
63.01% of 1176 companies
in the Biotechnology industry
Industry Median: 16.8 vs CHIX:IVAp: 6.30

Inventiva's EPS (Diluted) for the six months ended in Dec. 2025 was €-0.92. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-2.54.

Inventiva's EPS (Basic) for the six months ended in Dec. 2025 was €-0.92. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €-2.54.


Inventiva  (CHIX:IVAp) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Inventiva EPS without NRI Related Terms


Inventiva EPS without NRI Historical Data

* Premium members only.

The historical data trend for Inventiva's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventiva EPS without NRI Chart

Inventiva Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.31 -1.38 -2.42 -2.10 -1.14

Inventiva Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.09 -1.06 -1.17 -0.59 -0.70

CHIX:IVAP vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Inventiva's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inventiva PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inventiva's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Inventiva's PE Ratio without NRI falls into.


CHIX:IVAP
53GF Score
Inventiva SA CHIX:IVAP
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inventiva EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-1.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €-1.30 mean?
Inventiva (CHIX:IVAP) has a EPS without NRI of €-1.30 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Inventiva and its competitors. According to the industry distribution chart, Inventiva ranks #741 out of 1176 companies in the Biotechnology industry, placing it in the top 63%.
Is Inventiva's EPS without NRI too high?
Inventiva's current EPS without NRI is €-1.30. Based on the distribution chart, Inventiva ranks #741 out of 1176 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Inventiva has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inventiva's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Inventiva ranks #741 out of 1176 companies for EPS without NRI. This places Inventiva in the lower half of its industry. The industry median EPS without NRI is 16.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,176 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Inventiva and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inventiva's current EPS without NRI is €-1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inventiva stock overvalued right now?
Based on GuruFocus' analysis, Inventiva (CHIX:IVAP) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.24, compared to a current price of €3.06 — trading 1175% above its estimated fair value. The current EPS without NRI is €-1.30. Inventiva's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Inventiva (CHIX:IVAP), the current EPS without NRI is €-1.30 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inventiva (CHIX:IVAP) Overvalued in 2026?

Based on GuruFocus' analysis, Inventiva stock appears to be overvalued. The current stock price of €3.06 is trading 1175% above its estimated GF Value™ of €0.24. GuruFocus considers Inventiva to be Significantly Overvalued.

Key valuation signals for CHIX:IVAP:

  • EPS without NRI: €-1.30
  • GF Value™: €0.24 vs. price of €3.06 (1175% above fair value)
  • GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the CHIX:IVAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Inventiva Business Description

Address 50 rue de Dijon, Daix, FRA, 21121
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
53GF Score

Get the complete analysis for CHIX:IVAP

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.06
Price
€0.24
GF Value